4.8 Article

PAR1 contributes to influenza A virus pathogenicity in mice

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 1, Pages 206-214

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI61667

Keywords

-

Funding

  1. Agence Nationale de la Recherche (ANR)
  2. Inserm Avenir
  3. Marie Curie actions
  4. Long-term structural funding-Methusalem by the Flemish government
  5. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065590] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Influenza causes substantial morbidity and mortality, and highly pathogenic and drug-resistant strains are likely to emerge in the future. Protease-activated receptor 1 (PAR1) is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. The role of PAR1 in pathogenesis of virus infections is unknown. Here, we demonstrate that PAR1 contributed to the deleterious inflammatory response after influenza virus infection in mice. Activating PAR1 by administering the agonist TFLLR-NH2 decreased survival and increased lung inflammation after influenza infection. Importantly, both administration of a PAR1 antagonist and PAR1 deficiency protected mice from infection with influenza A viruses (IAVs). Treatment with the PAR1 agonist did not alter survival of mice deficient in plasminogen (PLG), which suggests that PLG permits and/or interacts with a PAR1 function in this model. PARE antagonists are in human trials for other indications. Our findings suggest that PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and oseltamivir-resistant H1N1 viruses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available